Gentis develops biomaterials-based products for the treatment of early-stage degeneration of the spine.
Gentis is a developer of minimally invasive, biomaterials-based products intended to treat the early-stage degeneration of the spine. The company's patented product is DiscCell, an injectable, in-situ setting, radio-opaque, non-hydrogel polymer material that augments or replaces the diseased nucleus pulposus of the spinal disc.Gentis was founded on 2000 and is headquartered in Wayne, Pennsylvania.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 19, 2010 | Series Unknown | $548.26K | 1 | — | — | Detail |
Jun 21, 2007 | Series A | $10M | 2 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Matignon Technologies | — | Series Unknown |
Matignon Investissement & Gestion | — | Series A |